IGF1 and neoplasm: Management is aimed at (a) reducing, or at a minimum stabilizing, the tumour bulk while preserving pituitary hormone function; (b) controlling the excess GH and IGF‐I secretion to obtain a GH level < 1.0 μg/L and normal age‐related IGF‐I level, which has been shown to restore mortality to that expected of the general population5; (c) improving the patients' signs and symptoms; and (d) preventing occurrence and/or progression of systemic complications related to long‐term GH excess.6, 7